Your browser doesn't support javascript.
português español english français
Biblioteca Virtual em Saúde

Conselho Nacional de Secretários de Saúde (CONASS)

Informação e Conhecimento para a Saúde

Home > Pesquisa > au:"Pierre, Reinaldo" (13)
Busca Avançada | Localizar descritor de assunto
Configurar filtros
Detalhe da pesquisa
RSS XML
Imprimir Exportar

Formato de exportação:

Exportar

Exportar:

Email
Adicionar mais destinatários

Enviar resultado
|
Resultados 1 - 13 de 13
7.

Interferón pegilado alfa-2 a en combinación con Lamivudine para tratamiento de hepatitis B crónica en pacientes pediátricos / Introduction and Aims: Combined treatment with pegylated interferon and lamivudine can constitute a suitable alternative in order to obtain seroconversion in pediatric patients with virus B chronic infection. The aim of the present study was to evaluate the response of pediatric patients with chronic virus B infection given by the lost of Age VHB and DNA VHB, and the appearance of antibodies against Age VHB and normalization of aminotranferases in patients treated with pegylated interferon alpha 2a in combination with lamivudine. Patients and Methods: Pediatric patients with chronic infection by virus B were included, with positive HBe Ag, anti- HBe Ab-, HBV DNA positive, elevation of aminotranferases for more than 6 months These patients received treatment with pegylated interferon alpha 2a and lamivudine 4 mgs/kg/day for 52 weeks. Results: The transmission routes were vertical in 2 patients, transfusional in 7and 1 unknown. PatientÊs mean age was 10,3+ 3,47 years, with an average time of exposure to virus B of 5,2+3,93 years. The average of aminotranferases at the beginning of treatment was AST 112,3+46,3 and ALT 127,8 + 44. Twelve weeks following treatment AST levels were 33,3+12,14 and ALT 35,5+ 13,51.The histological findings were: 2 patients had moderate inflammatory activity, 8 mild activity , 2 developed moderate fibrosis and 8 mild fibrosis. Only 1 patient developed anemia and leucopenia that did not require the suspension of treatment. Ten (10) patients (100%) developed fever, 8 (80%) migraine during the 4 first weeks of treatment; they remained asymptomatic during the 48 remaining weeks. The 10 patients had normal aminotranferases at 12 weeks following treatment. Two (2) (20%) of the patients presented loss of Ags VHB and Ac positive Ags VHB 12 weeks post treatment. Of 10 patients 4 (40%) had seroconversion (Age VHB, negative DNA VHB and Ab positive Age VHB) by week 52 of treatment and 12 weeks post treatment. Conclusion: Combined treatment with pegylated interferon and lamivudine constitute an effective and safe therapeutic option for pediatric patients with chronic infection by virus B.

Pestana, Elena; León, Keira; Pierre, Reinaldo; Olza, María Teresa; Hassan, Isaac.
GEN; 61(2): 105-107, jun. 2007. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-664261
Resultados 1 - 13 de 13
powered by iAHx-2.18-89 Conselho Nacional de Secretários de Saúde (CONASS)
Termos e condições de uso | Política de privacidade